• Mashup Score: 12
    Immunogenicity of a BNT162b2 vaccine booster in health-care workers - 3 year(s) ago

    The Pfizer-BioNTech mRNA COVID19 vaccine (BNT162b2) was found to be highly efficacious against symptomatic SARS-CoV-2 infection, with a vaccine efficacy of 94% in a randomised clinical trial1 and an effectiveness of 94–95% in real-world studies in Israel.2 Similar effectiveness rates (97% against symptomatic infection and 86% against asymptomatic infection) were found in health-care workers.3…

    Source: The Lancet Microbe
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancet
      TheLancet

      New to The Lancet's #COVID19 resource centre—A research letter, published in @LancetMicrobe, reports on the immunogenicity of a #BNT162b2 (Pfizer–BioNTech) vaccine booster in health-care workers. https://t.co/FmgvWsdfEE #BoosterShots https://t.co/gQlAjNBOyO

  • Mashup Score: 0
    BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus - 3 year(s) ago

    Objectives Our aim was to evaluate systemic lupus erythematosus (SLE) disease activity and SARS-CoV-2-specific immune responses after BNT162b2 vaccination. Methods In this prospective study, disease activity and clinical assessments were recorded from the first dose of vaccine until day 15 after the second dose in 126 patients with SLE. SARS-CoV-2 antibody responses were measured against…

    Source: Annals of the Rheumatic Diseases
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of ARD_BMJ
      ARD_BMJ

      MMF or MTX therapy and low naïve B cell frequencies, were independently associated with impaired antibody response to #BNT162b2 mRNA in patients with #SLE in this study 👉https://t.co/ePM7YPfqqS 👆Titers should be measured and a third vaccination might be needed👍 #COVID19

  • Mashup Score: 1
    Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease - 3 year(s) ago

    Objective To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. Methods Established patients at New York University Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunisation. Healthy…

    Source: Annals of the Rheumatic Diseases
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of ARD_BMJ
      ARD_BMJ

      🚨New study on #BNT162b2 vaccine efficacy in pts with rheumatic diseases. Antibody response higher in healthy controls and non-methotrexate (>90%) vs. #methotrexate (62.2%) patients. Small cohorts but implications for adjustments in RMD patients on #MTX https://t.co/DoD6xlWr5v https://t.co/NFVSmkQNsg

  • Mashup Score: 28
    Antibody response after second BNT162b2 dose in allogeneic HSCT recipients - 3 year(s) ago

    The prognosis of COVID-19 infection is poor in hematopoietic stem-cell transplant (HSCT) recipients.1,2 In a large multicentric series of 318 HSCT recipients (184 allogeneic HSCT recipients and 134 autologous HSCT recipients), the probability of overall survival at 30 days after the diagnosis of COVID-19 infection was notably dismal, at 68% (95% CI 58–77) and 67% (55–78) for allogeneic HSCT…

    Source: The Lancet
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancet
      TheLancet

      SARS-CoV-2 mRNA #vaccine efficacy in #immunocompromised individuals needs further evaluation, writes Rabah Redjoul et al. Research letter: Antibody response after 2nd #BNT162b2 dose in allogeneic hematopoietic stem-cell transplant (#HSCT) recipients. https://t.co/zoMeb0bXtL

  • Mashup Score: 0
    Eagle’s Eye View: Your Weekly CV Update From ACC.org (Week of May 31) - American College of Cardiology - 3 year(s) ago

    This week’s View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including articles on the effectiveness of same-day rapid antigen detection testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for reducing the incidence of SARS-CoV-2 infection a week after social indoor gatherings; the safety, immunogenicity, and efficacy of the BNT162b2 COVID-19…

    Source: American College of Cardiology
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ACCinTouch
      ACCinTouch

      This #EaglesEyeView focuses on articles on effectiveness of same-day antigen detection testing for #SARSCoV2 for ⬇️ incidence of SARSCoV2 infec. 1wk after indoor gatherings; safety, immunogenicity & efficacy of #BNT162b2 COVID vax in adolescents & more: https://t.co/kGsvCOEA9m https://t.co/6tH1iDlVGt

  • Mashup Score: 48
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination - 3 year(s) ago

    The SARS-CoV-2 B.1.617.2 Variant of Concern (VOC), first detected in India, is now dominant in the UK, having rapidly1 displaced the B.1.1.7 strain2 that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently licensed COVID-19 vaccines against B.1.617.2 is unknown; although it possesses 12 mutations in its spike protein relative to the wildtype SARS-CoV-2 first…

    Source: The Lancet
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TheLancet
      TheLancet

      NEW—Correspondence reports initial analysis of neutralising antibody activity against #SARS-CoV-2 variants of concern B.1.617.2 and B.1.351 elicited by partial or full vaccination with #BNT162b2 (#Pfizer-BioNTech). Read https://t.co/mW69kw1jCh. Figure from appendix. @TheCrick https://t.co/3rTI65ckg7

Load More